DCAF15 has garnered substantial therapeutic interest in cancer, as it has been shown to interact with the anti-cancer aryl-sulfonamide molecular glue compounds (including the drugs indisulam [also known as E7070], tasisulam, E7820, and chloroquinoxaline sulfonamide [CQS]), which enables the E3 to recognize and promote ubiquitin-dependent degradation of the splicing factor RNA-Binding Motif protein 39 (RBM39)9,10,14–16. Here, SLU7 is linked to cancer.